[{"orgOrder":0,"company":"Orexia Therapeutics","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Orexia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orexia Therapeutics \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Orexia Therapeutics \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ENA-001","moa":"Potassium ion channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enalare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","graph1":"Sleep","graph2":"Preclinical","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Enalare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ENA-001","moa":"Potassium ion channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eagle Pharmaceuticals \/ Enalare Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Enalare Therapeutics"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ENA-001","moa":"Potassium ion channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Enalare Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PsychoGenics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"RO7117997","moa":"","graph1":"Sleep","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffmann-La Roche \/ PsychoGenics"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Aexon Labs","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"NLS Pharmaceutics \/ Aexon Labs","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Aexon Labs"},{"orgOrder":0,"company":"Aexon Labs","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"AEX-2","moa":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Aexon Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Aexon Labs \/ NLS Pharmaceutics","highestDevelopmentStatusID":"4","companyTruncated":"Aexon Labs \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"TPM-1116","moa":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Bioprojet Pharma","amount2":0.39000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0.39000000000000001,"dosageForm":"","sponsorNew":"Bioprojet Pharma \/ Harmony Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Bioprojet Pharma \/ Harmony Biosciences"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"AEX-41","moa":"","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Not Applicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"AEX-41","moa":"","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Not Applicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Aexon Labs","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AEX-2","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"NLS Pharmaceutics \/ Aexon Labs","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Aexon Labs"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

ATTD
Not Confirmed
ATTD
Not Confirmed

Details : AEX-2 is a potential first-in-class non-sulfonamide dual orexin receptor agonist (DOXA), which is being evaluated for narcolepsy and related neurological disorders.

Product Name : AEX-2

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 27, 2025

Lead Product(s) : AEX-2

Therapeutic Area : Sleep

Highest Development Status : Preclinical

Sponsor : Aexon Labs

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

ATTD
Not Confirmed
ATTD
Not Confirmed

Details : AEX-41 is a first-in-class non-sulfonamide DOXAs, are designed to target both OX1R/OX2R while inhibiting cathepsins, which play significant role in narcolepsy and other neurological disorders.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Not Applicable

December 03, 2024

Lead Product(s) : AEX-41

Therapeutic Area : Sleep

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

ATTD
Not Confirmed
ATTD
Not Confirmed

Details : AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed to target both OX1R and OX2R to address the unmet needs in narcolepsy and related neurological disorders.

Product Name : AEX-41

Product Type : Small molecule

Upfront Cash : Not Applicable

November 18, 2024

Lead Product(s) : AEX-41

Therapeutic Area : Sleep

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

ATTD
Not Confirmed
ATTD
Not Confirmed

Details : The Company's lead candidate, Quilience®, is a proprietary extended-release formulation of Mazindol (Mazindol ER) and is being developed for the treatment of orexin-B-saporin induced narcolepsy.

Product Name : Quilience

Product Type : Small molecule

Upfront Cash : Not Applicable

May 28, 2024

Lead Product(s) : Mazindol

Therapeutic Area : Sleep

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

ATTD
Not Confirmed
ATTD
Not Confirmed

Details : Through the Licensing Agreement, Bioprojet will develop, manufacture, and commercialize TPM-1116, a selective oral orexin-2 receptor agonist for narcolepsy and other sleep/wake disorders.

Product Name : TPM-1116

Product Type : Small molecule

Upfront Cash : $25.5 million

April 11, 2024

Lead Product(s) : TPM-1116

Therapeutic Area : Sleep

Highest Development Status : Preclinical

Sponsor : Harmony Biosciences

Deal Size : $393.0 million

Deal Type : Licensing Agreement

blank

06

ATTD
Not Confirmed
ATTD
Not Confirmed

Details : The agreement grants NLS global rights to next-gen oral OX1R/OX2R agonists, including AEX-2, tailored for narcolepsy, idiopathic hypersomnia, Parkinson's disease, dementia with Lewy bodies.

Product Name : AEX-2

Product Type : Undisclosed

Upfront Cash : Undisclosed

March 20, 2024

Lead Product(s) : AEX-2

Therapeutic Area : Sleep

Highest Development Status : Preclinical

Sponsor : NLS Pharmaceutics

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank

07

ATTD
Not Confirmed
ATTD
Not Confirmed

Details : Under the agreement, Roche obtains global development, manufacturing, and commercialization rights to RO7117997, an IND-ready ENT1 inhibitor discovered using the PsychoGenics’ AI-enabled phenotypic screening platforms.

Product Name : RO7117997

Product Type : Undisclosed

Upfront Cash : Undisclosed

December 01, 2023

Lead Product(s) : RO7117997

Therapeutic Area : Sleep

Highest Development Status : Preclinical

Sponsor : PsychoGenics

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank

08

ATTD
Not Confirmed
ATTD
Not Confirmed

Details : Under the agreement, NLS may acquire development and commercialization rights to Aexon Labs' dual orexin receptor agonists platform for the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro-degenerative disorders.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

December 01, 2023

Lead Product(s) : Undisclosed

Therapeutic Area : Sleep

Highest Development Status : Preclinical

Sponsor : Aexon Labs

Deal Size : Undisclosed

Deal Type : Agreement

blank

09

ATTD
Not Confirmed
ATTD
Not Confirmed

Details : ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body.

Product Name : ENA-001

Product Type : Small molecule

Upfront Cash : Not Applicable

October 03, 2022

Lead Product(s) : ENA-001

Therapeutic Area : Sleep

Highest Development Status : Preclinical

Sponsor : Enalare Therapeutics

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

ATTD
Not Confirmed
ATTD
Not Confirmed

Details : Enalare's lead compound, ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid b...

Product Name : ENA-001

Product Type : Small molecule

Upfront Cash : Not Applicable

October 03, 2022

Lead Product(s) : ENA-001

Therapeutic Area : Sleep

Highest Development Status : Preclinical

Sponsor : National Institutes of Health

Deal Size : Not Applicable

Deal Type : Not Applicable

blank